Just out in
@CircAHA
⭐️
Led by co-chairs, Dr. Glenn Levine &
@johnwmcevoy
, pleased to share our
@AHAScience
Scientific Statement on the Management of Patients at Risk for and With LV thrombus!
1/
Link:
My 15 highlights 💡from the 2020 ESC NSTE-ACS guideline:
1. Hs troponins recommeded over conventional assays 🧪
2. ESC 0'1 and 0'2 algorithms preferred over 0'3
3. TTE recommended for all patients.
⚡️💥BREAKING 💥⚡️
The 2021 ACC/AHA/CHEST/SAEM/SCCT/SCMR Chest Pain guideline was published online today!
Link to paper:
Here are my personal takeaways!
👇
Thread /
Graduated from
@HarvardChanSPH
@Harvard
today with a Masters of Science in Epidemiology! Looking forward to putting the knowledge in to action! Special thanks to my wife
@InbarMcCarthy
for her support and my amazing mentors at
@MGHHeartHealth
and the future grad from our home👇
Now out in
@JACCJournals
, pleased to share our
@ACCinTouch
Expert Consensus Decision Pathway on the Evaluation of Acute Chest Pain in the ED led by Chair
@Mikekontos1
and Vice-Chair Dr. James De Lemos.
Link:
Thread👇
1/
Out now in
@JACCJournals
and presented today
@NCYIForum
, in a prospective study of consecutively adjudicated cases of type 2 MI we sought to answer how common any plaque, obstructive CAD, and hemodynamically significant focal stenosis is in this population?
1/thread
Delighted to receive K23 NOA from
@nih_nhlbi
. We will explore health status using PROMs for type 2 vs type 1 MI and use of cardiac rehab for type 2 MI. Very grateful to mentors
@pnatarajanmd
@JJheart_doc
and advisory team
@jspertus
@jasonwasfy
Drs. Kitzman, Huffman, and Doros 1/2
I am excited to share the results of the DEFINE Type 2 MI study at
#ACC23
on Saturday! This is the 1st prospective study examining the prevalence of CAD and hemodynamically significant stenosis (FFRct) among patients with type 2 MI in the US. Swing by if free
@JJheart_doc
Congratulations to my better half
@InbarRaber
for matching to her top Cardiology fellowship choice: Beth Israel Deaconess Medical Center! So proud of you!
@BidmcCvi
In
@JACCJournals
Ueki et al examine the incidence & prognosis of various definitions of periprocedural MI among patients undergoing PCI.
@JJheart_doc
and I discuss periprocedural MI as an endpoint in clinical trials in the editorial
1/ A thread
👇
Getting excited for ACC.22 next month!
#ACC2022
Received my badge in the mail today.. It looks like I was accidentally promoted to treasurer… Would that make me your boss
@JJheart_doc
?
@ACCinTouch
Congratulations to my better half
@InbarRaber
for presenting her important work on Gender Differences in Industry Payments among Cardiologists
@BIDMC_Medicine
Grand Rounds today!
Much work to be done to narrow the gender salary gap in Cardiology!
@johnwmcevoy
@ACCinTouch
Out today in
@JAMA_current
, in this Viewpoint available with free access,
@jasonwasfy
,
@JJheart_doc
, and I pose the question:
Is Myocardial Infarction Overdiagnosed?
Now out in
@CircOutcomes
(simultaneous pub with
#AHA20
), we examine how frequently patients with type 2 MI are evaluated by a cardiologist and the association of this evaluation with testing and treatment.
@jasonwasfy
@MGHHeartHealth
Huge honour to be included in
@CircAHA
list of Outstanding Reviewers this year among such esteemed academics including
@mchonig
! Lots of fascinating science published in the journal this year!
@MGHHeartHealth
Troponin 99th percentiles are a 🗝️component of MI diagnosis. In this
@JACCJournals
,
@johnwmcevoy
et al 🔍 these cut-offs using NHANES and how they vary by sex, race, and age.
@JJheart_doc
, Austin Vyas, and I discuss in editorial
Confused about the difference between type 2 MI and myocardial injury? What are the evaluation and coding implications? I discuss these issues in this article now published on .
@ACCinTouch
@keaglemd
👇
Fantastic meeting today in ACC Heart House discussing the evaluation of ACS in the ED. Honored to be be part of this amazing committee led by Drs. Kontos and De Lemos. More guidance on this issue to come in the era of high sensitivity troponin assays!
@MGHHeartHealth
The ACC would like to thank the Emergency Department Evaluation of Patients With Possible ACS Roundtable Planning Committee for their work on addressing recent trends related to the evaluation of patients with possible
#cvACS
in the ED.
Navigating the U.S. visa/Greencard system can be a very stressful experience for IMGs, especially around residency/fellowship application periods. After 2 years of work, delighted to have my greencard approved today! 🇺🇸 🇮🇪 Thanks to
@MGHMedicine
,
@jmvyasmdphd
for the support
In this issue of
@JACCJournals
, Drs. Chang,
@mvaduganathan
and I discuss shortfalls of current systems of cardiometabolic care, the need for cardiometabolic specialists, and provide a proposed framework of a dedicated cardiometabolic training program.
Myocardial injury is now the most common cause of ⬆️ troponin. Eggers et al. report 5-year MACE rate of 15%
@JACCJournals
In the accompanying editorial,
@JJheart_doc
and I confront the trivialization of myocardial injury.
👇
Very impressive results! 15% mean drop in body weight in the semaglutide group (average loss of 15kg)!!
Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM
Hs-troponin assays are ✅ for ❌ MI. Yet, ⬆️ of unclear etiology are common. In this important study,
@johannesneuman
@dirkwestermann
derive 🧪 scores to differentiate T1MI, T2MI + myocardial injury.
@JJheart_doc
and I discuss next steps in the editorial
As we head into St. Patrick's day ☘️☘️, many across the globe will celebrate wearing green, attending parades, and for some, sipping a Guinness.
However, many in the academic community may not be aware that
@GuinnessIreland
has produced more than just stout..
As one of
@jjheart_doc
mentees for the past 5 years, I can definitively say this is an INCREDIBLE opportunity! Jim has knocked down so many doors for me and we have published 35 papers together in that period. Come join our group!
📢Job opportunity!
Interested in a research fellowship in my study group? We have a 2-year position available! Plenty of mentorship and publishing opportunities. Follow the link below for more information!
#HeartFailure
#GDMTworks
#biomarkers
Now available in
@JAMA_current
, examining changes to the HRRP this year, we find that there is a ⬇️ in penalization for all hospitals; the largest reduction was seen in hospitals of low socioeconomic status (91.6% to 77.6%)
@mvaduganathan
@ambarish4786
In our viewpoint now available at JAMA,
@JJheart_doc
,
@mvaduganathan
and I discuss why we need evidence based therapies for T2MI and outline potential areas for investigation
@JAMA_current
Type 2 Myocardial Infarction—Diagnosis, Prognosis, and Treatment
Congratulations to
@DrPRao
for his excellent presentation on Plasma Proteomic Profiles of BP response during exercise for the Genomic and Precision Medicine Early Career investigator award!
Finds TGFBR3 as a marker of protection against HF and HTN!
@BidmcCvi
@BIDMCVFellows
Our latest study led by star research fellow and cardiology fellowship applicant
@RezaMohebiMD
now out in
@JACCJournals
! Highlights by
@JJheart_doc
below! Much work to do in the prevention of CV disease!!
Out today in
@JACCJournals
is our work focused on projecting future prevalence of cardiovascular risk factors and disease in the United States.
Published at
Credit goes to
@RezaMohebiMD
for his hard work on this very interesting project.
A 🧵...
3/ Let’s start with acute chest pain in the ED. The committee advise against using the term atypical chest pain; instead favoring categorizing as cardiac, possibly cardiac, and non-cardiac chest pain. I like this concept a lot!
Huge congratulations to my sister
@aoifeamc
for publishing her first music book for children 📕! I am sure it will be a fantastic resource for teachers and pupils! Very proud of you!
@FolensEducation
Congratulations to Miss Mc Carthy on the publication of her book "Into Music" for 5th & 6th Class. A fantastic achievement and great to see it in print! 🎶🎵
Thank you for the opportunity to discuss high-sensitivity troponin in primary prevention at the 18th Brazilian Congress of Atherosclerosis. Fantastic session
@rauldsf_santos
@MGHHeartHealth
Much discussion over the last 24 hours on the 3rd universal definition of MI data (UD-MI) from the EXCEL trial.
But how were the troponin cut-offs for the definition of type 4 MI chosen by the UD-MI committee? They were arbitrarily chosen....
👇
14. Long term beta blocker not routinely recommended in absence of LV dysfynction/HF. Can however consider it.
15. Notably, guideline did not differentiate type 1 and type 2 MI in their recommendations. Will you be applying these recommendations to your type 2 MI patients?!
We are delighted to share an exiting line up for our upcoming Dublin Cardiovascular Research Forum lectures.
Register via our website -
@materprivate
@RCSI_Irl
Back by popular demand 🙌
Going Back to the Heart of Cardiology
@theheartorg
returns this December (6th to 10th)! Awesome session line up (see details in thread below) chaired by
@HeartBobH
and moderated by
@CMichaelGibson
&
@FaRodriguezMD
Register 👇
Two things that always frustrate me on rounds:
1) An elevated hsTn being referred to as ‘Rule in’ when the patient does not have an MI
2) An elevated hsTn being labeled T2MI when there is no evidence of ischemia
@JJheart_doc
3/ In general, revascularization is recommended (Class 1) for stable ischemic heart disease for 1) refractory angina despite medical therapy, 2) left main disease, 3) ischemic cardioyopathy and suitable for CABG. See this figure for details
Our study, lead by
@SammyElmariahMD
demonstrating the potential utility of multiple biomarkers to diagnosis Aortic Stenosis
@JJheart_doc
@IAmDrIbrahim
Multiple biomarker panel to screen for severe aortic stenosis: results from the CASABLANCA study
4/ For stable CAD undergoing PCI, DAPT for 6 months recommended. Shorter (1-3 months) or longer courses are reasonable in select patients.
For ACS undergoing PCI, 12 months of DAPT recommended but shorter or longer courses possible also
New study led by
@InbarRaber
@mahrifai
and
@johnwmcevoy
. Male cardiologists submitting higher reimbursed charges than women even after accounting for experience, panel complexity, procedural subspecialty and volume of codes. More education 📖📚 needed to narrow the gap!
2/ For stable CAD and left main stenosis, CABG is recommended (Class 1). PCI is a reasonable option if low-medium anatomic complexity and if equally suitable to PCI compared to CABG (Class IIa)
Kini and colleagues derive a simple risk score to predict 90-day readmissions after AMI
@ambarish4786
and I discuss the optimal duration of value-based programs and competing risk of mortality in the accompanying editorial
3/ Radial artery is recommended in preference to saphaneous vein graft for 2nd conduit for CABG.
Radial access recommended over femoral access for PCI for ACS and stable CAD
11. CMR recommended for MINOCA cases without clear cause.
12. Advanced age should not change your diagnostic and therapeutic strategies.
13. LDL target is 55. Repeat in 4-6 weeks and add zetia if needed, repeat again in 4-6 weeks and add PCSK9 if needed
Join the
#BackToHeart21
virtual event December 6-10, covering heart failure, anticoagulation, lipid mgmt, and the most relevant
#CardioTwitter
topics today. Submit your abstracts 📃!
All proceeds benefit
@ABCardio1
+
@WomenHeartOrg
. Register Here:
6. Prasugrel preferred over ticagrelor if undergoing PCI 💊
7. Both preferred over clopidogrel unless not available
8. UFH preferred to LMWH for NSTEMI 💉
4. If rule-out using ED algorithm but still have concern for ACS, a non-invasive modality is preferred to invasive coronary angio
5. Pre-treatment with P2Y12 not recommended prior to invasive coronary angiogram
So much learning and a lot of fun rounding with
@realdocthomas
on the Heart Failure service today! Great mix of cases, bedside teaching, and chalk talks.
Very lucky to have such amazing teachers
@MGHHeartHealth
!
5/ For hemodynamically stable STEMI patients with multivessel disease, staged PCI of non-infarct vessel recommended (Class 1). Elective CABG is reasonable after primary PCI also (Class IIa).
Multivessel PCI at the time of primary PCI not recommended for STEMI with shock
Lots of buzz about this colchicine trial this morning.. I’ll hold my breath until I see how close it “approached statistical significance”....
Colchicine reduces the risk of COVID-19-related complications
Congrats
@johnwmcevoy
@rblument1
and team! Important study!!
Association Between Isolated Diastolic Hypertension Defined by the 2017 ACC/AHA Blood Pressure Guideline and...
Recovered from
#AHA21
? Looking for a conference that provides updates on all of the major advancements in cardiology this past year?
Join the
#BackToHeart21
virtual event Dec 6-10th. Register:
@CMichaelGibson
@HeartBobH
preview the CV prevention session
8/ For intermediate risk group, non-invasive testing generally needed, stratified by known or unknown CAD, unless recent normal stress test <1 year of normal CTCA within 2 years. See these key figures for details.
9. Invasive angiography recommended within 24 hours for "high-risk" patients. "Diagnosis of NSTEMI by algorithm" is considered high-risk.
10. If transient ST elevation and resolution of symptoms, invasive angiogram within 24 hours (rather than immediate) favored
Following the recent publication of the updated AHA/ACC primary prevention guideline, we take a deep dive into the evidence for & against aspirin in the primary prevention of CVD, led by Dr. Inbar Raber of
@BIDMC_IM
and
@johnwmcevoy
. Now available in
@TheLancet